A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer

(2011) Nicolas Mottet et al.   EUROPEAN UROLOGY

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases

(2010) Mark A ROSENTHAL et al.   Asia-Pacific Journal of Clinical Oncology

EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease

(2010) Axel Heidenreich et al.   EUROPEAN UROLOGY

A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer

(2010) Franklin M. Chu et al.   INVESTIGATIONAL NEW DRUGS

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium

(2010) Deborah A. Bradley et al.   INVESTIGATIONAL NEW DRUGS

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET

Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

(2008) Dominik R. Berthold et al.   JOURNAL OF CLINICAL ONCOLOGY